Abstract:Antibody-cytokine fusion proteins (immunocytokine) exert a potent anti-cancer effect; indeed, they target the immunosuppressive tumor microenvironment (TME) due to a specific anti-tumor antibody linked to immune activating cytokines. Once bound to the target tumor, the interleukin-2 (IL-2) immunocytokines composed of either full antibody or single chain Fv conjugated to IL-2 can promote the in situ recruitment and activation of natural killer (NK) cells and cytotoxic CD8+ T lymphocytes (CTL). This recruitment induces a TME switch toward a classical T helper 1 (Th1) anti-tumor immune response, supported by the cross-talk between NK and dendritic cells (DC). Furthermore, some IL-2 immunocytokines have been largely shown to trigger tumor cell killing by antibody dependent cellular cytotoxicity (ADCC), through Fcγ receptors engagement. The modulation of the TME can be also achieved with immunocytokines conjugated with a mutated form of IL-2 that impairs regulatory T (Treg) cell proliferation and activity. Preclinical animal models and more recently phase I/II clinical trials have shown that IL-2 immunocytokines can avoid the severe toxicities of the systemic administration of high doses of soluble IL-2 maintaining the potent anti-tumor effect of this cytokine. Also, very promising results have been reported using IL-2 immunocytokines delivered in combination with other immunocytokines, chemo-, radio-, anti-angiogenic therapies, and blockade of immune checkpoints. Here, we summarize and discuss the most relevant reported studies with a focus on: (a) the effects of IL-2 immunocytokines on innate and adaptive anti-tumor immune cell responses as well as immunosuppressive Treg cells and (b) the approaches to circumvent IL-2-mediated severe toxic side effects.

Interleukin-2 signaling in the regulation of T cell biology in autoimmunity and cancer

Interleukin-2 and regulatory T cells in rheumatic diseases

The T-Cell Growth Factor Interleukin-2, Which Is Occasionally Targeted by Autoantibodies, Qualifies as Drug for the Treatment of Allergy, Autoimmunity, and Cancer: Collegium Internationale Allergologicum (CIA) Update 2024

Fine tuning of the innate and adaptive immune responses by Interleukin-2

Engineering IL-2 for immunotherapy of autoimmunity and cancer

Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics

Advances on role of interleukin-2 and its receptors in development of autoimmune diseases

Interleukin-2 receptor downstream events in regulatory T cells: Implications for the choice of immunosuppressive drug therapy

Optimising IL-2 for Cancer Immunotherapy

Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies

Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases

IL-2 Can Signal Via Chemokine Receptors to Promote Regulatory T Cells' Suppressive Function.

T Cells, Interleukin-2 and Systemic Lupus Erythematosus—From Pathophysiology to Therapy

Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer

The Mechanism of Action of IL-2 in the Tumor Microenvironment and Its Application in Melanoma

Targeting IL-2: an Unexpected Effect in Treating Immunological Diseases

Regulating IL-2 immune signaling function via a core allosteric structural network

Low-Dose IL-2 Therapy in Transplantation, Autoimmunity, and Inflammatory Diseases

Cutting Edge: Th17 and Regulatory T Cell Dynamics and the Regulation by IL-2 in the Tumor Microenvironment.

Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy

Low-dose IL-2 therapy in autoimmune diseases: An update review